This website has been developed and fully funded by Janssen-Cilag Ltd. and is intended for UK patients prescribed Tremfya®▼ (guselkumab) only.

Information on COVID-19 for patients using Tremfya® (guselkumab)
Information on COVID-19 for patients using Tremfya® (guselkumab)

Psoriatic arthritis

Your doctor has prescribed you Tremfya® for the treatment of psoriatic arthritis. This website provides you with information and guidance so that you may better understand your medication and your treatment journey.

Tremfya® is used to treat a condition called “psoriatic arthritis”, an inflammatory disease of the joints, often accompanied by psoriasis.1

If you have psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Tremfya® with the aim to reduce the signs and symptoms of the disease. Your medication can be used alone or with another medicine named methotrexate.1

Reporting side effects

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also call Janssen-Cilag Ltd Drug Safety on 01494 567447 or at dsafety@its.jnj.com.

By reporting side effects you can help provide more information on the safety of this medicine.

References

  1. Tremfya® Patient Information Leaflet. Available from: https://www.medicines.org.uk/emc/files/pil.9587.pdf [Last accessed March 2021].